Lymphoma is the cancer in which the first human tumour virus was found, one of the first sorted into subtypes by reading which genes were switched on, and among the first treated by reprogramming a patient's own immune cells. This roadmap follows the evidence from 1958 to trials with completion dates in 2032.
Lymphoma has been first at an unusual number of things, and the reason is that you can get hold of it. A lymph node is easy to biopsy, the cells grow in culture, the disease circulates in blood, and it responds to treatment fast enough that a trial reads out in years rather than decades.
That is why the first human tumour virus was found in it. Denis Burkitt described a jaw tumour in Ugandan children in 1958 and mapped where it occurred; Epstein, Achong and Barr saw virus particles in cells cultured from one of his biopsies in 1964. In 1980 the first human retrovirus, now called human T-lymphotropic virus type 1, was isolated from the lymphocytes of a patient with a T-cell lymphoma by Poiesz and Gallo, and tied to adult T-cell leukaemia across a Japanese population by Hinuma.
It is also why lymphoma was the first common cancer taken apart by gene expression. Alizadeh and Staudt showed in 2000 that diffuse large B-cell lymphoma is at least two diseases; Rosenwald turned that into a survival predictor in 2002; Hans gave pathology laboratories a three-stain version in 2004. The genetic classifications followed in 2018, when Chapuy and Schmitz published five clusters and four subtypes within three weeks of each other, and Wright's LymphGen tool in 2020 made it possible to classify one patient's tumour with a probability attached.
Treatment moved on three tracks. In Hodgkin lymphoma the whole effort since the 1990s has been to take treatment away without losing the cure, because Dutch cohorts of five-year survivors treated from 1965 onwards put the 40-year cumulative incidence of a second cancer at 48.5 per cent and of cardiovascular disease at 50 per cent. HD10 halved the chemotherapy and cut the radiation dose; HD18 and AHL2011 used the scan after two cycles to shorten or soften the intensive regimen; HD16 and EORTC H10 tried to drop radiotherapy on a clear scan and could not. In aggressive B-cell lymphoma, R-CHOP has survived every challenger except one: obinutuzumab failed in GOYA, dose-adjusted EPOCH-R failed in CALGB 50303, ibrutinib failed overall in PHOENIX, and only polatuzumab vedotin in POLARIX improved on it, in progression-free survival but not in overall survival at two years. In indolent lymphoma the question has been how long to treat rather than how hard, and PRIMA answered it with six extra years before relapse and no change in survival.
The last decade belongs to the immune treatments. ZUMA-1, JULIET and TRANSCEND NHL 001 made CAR-T a third line in large B-cell lymphoma; ZUMA-7 and TRANSFORM moved it to second line, while BELINDA failed in the same setting with a 52-day manufacturing wait. ELARA and ZUMA-5 brought it to follicular lymphoma. The CD20 bispecific antibodies arrived alongside, off the shelf and without apheresis, and inMIND, ELM-2 and ROSEWOOD show the relapsed indolent setting is now crowded with options.
What has not been solved: the genetic subtypes have not yet changed standard first-line treatment, the T-cell lymphomas have little randomised evidence, no trial has yet reported that acting on a circulating tumour DNA result improves anything, and the drugs that cure this disease are unavailable to most of the people who get it.
Denis Burkitt described a tumour involving the jaws in African children in 1958 and mapped where it occurred; the geography pointed at an infectious cause. In 1964 Epstein, Achong and Barr saw virus particles in lymphoblasts cultured from one of his biopsies, the first virus ever found in a human tumour, and the start of the field that now includes human papillomavirus, hepatitis B and C, Helicobacter pylori and human herpesvirus 8. Neither paper has an abstract indexed on Europe PMC, so no figure from them is quoted here. The second virus came from the other side of the lymphoid system. Poiesz, Gallo and colleagues isolated type C retrovirus particles from the lymphocytes of a patient with a T-cell lymphoma in 1980, the first human retrovirus, characterising a reverse transcriptase that preferred magnesium to manganese and six particle proteins, some of them unlike those of most known primate retroviruses. The year after, Hinuma's group in Japan found antibodies to a related antigen in all 44 patients with adult T-cell leukaemia they tested, in 26 per cent of healthy adults from endemic areas and in only a few from elsewhere. Human T-lymphotropic virus type 1 is now screened for in blood donations.
The clinical description that set off the search for a cancer virus. It is also an argument for geographic epidemiology: Burkitt found the cause by asking where the disease was, not by looking down a microscope.
The start of viral oncology. Everything in cancer prevention that works by preventing or treating an infection, from hepatitis B vaccination to Helicobacter eradication for gastric MALT lymphoma, descends from the idea this paper established.
The first human retrovirus, and the start of the line of work that identified HIV three years later. For lymphoma it means that adult T-cell leukaemia/lymphoma has a known, transmissible, preventable cause, and that screening blood donors and advising on breastfeeding in endemic areas are cancer prevention measures.
The seroepidemiology that tied a virus to a cancer across a population rather than in one patient. It is the reason blood donations are screened for human T-lymphotropic virus type 1 in Japan and elsewhere, and the reason breastfeeding advice is part of cancer prevention in endemic regions.
Hodgkin lymphoma was curable before anyone knew what it was made of, and by the 1990s the question had become how much treatment could be removed. HD10 answered it for early favourable disease, randomising 1,370 patients in a two by two design and finding no difference between four and two cycles of ABVD (five-year freedom from treatment failure 93.0 against 91.1 per cent, p = 0.39) or between 30 Gy and 20 Gy of involved-field radiotherapy (p = 1.00). Two cycles with 20 Gy became the standard, and the four-cycle, 30 Gy group had the most toxicity. The reason the question mattered arrived in full later. The Dutch cohorts of five-year survivors treated from 1965 onwards measured what cure costs: a cumulative incidence of second cancer of 48.5 per cent at 40 years, with risk still raised at 35 years, and of cardiovascular disease of 50 per cent, with coronary heart disease and heart failure still four to six times the population rate after 35 years. The incidence of second solid cancers was no lower for patients treated between 1989 and 2000 than for those treated in the two earlier periods back to 1965, despite the less toxic protocols introduced in between.
Alizadeh and Staudt showed in 2000 that diffuse large B-cell lymphoma contains at least two diseases that look identical under the microscope. Rosenwald profiled 240 biopsies in 2002, found germinal-centre, activated and type 3 subgroups, and built a 17-gene survival predictor independent of the International Prognostic Index; the stromal and immune signatures in that paper anticipated the tumour microenvironment era. Hans put the classification within reach of ordinary pathology in 2004, using CD10, BCL6 and MUM1 to split 152 cases into germinal-centre and non-germinal-centre groups with five-year survival of 76 against 34 per cent. Then the field stalled. The classification predicted outcome but did not direct treatment, and the trials that selected patients by it, PHOENIX among them, failed. The genetic classifications of 2018 were the answer to why: Chapuy's five clusters from 304 tumours and Schmitz's four subtypes from 574 both cut the disease finer than the stain could, and Schmitz's MCD and BN2 subtypes carried a mechanism, chronic active B-cell receptor signalling, with a drug class already in the clinic. Wright's LymphGen tool in 2020 turned cohort clustering into a probability for one patient's tumour, and extended the classification to seven subtypes that share genetics with indolent and extranodal lymphomas.
R-CHOP has been the first-line standard for aggressive B-cell lymphoma since rituximab was added to CHOP, and almost nothing has improved on it. CALGB 50303 compared dose-adjusted EPOCH-R, which many centres had adopted on single-arm evidence, and found no difference in progression-free or overall survival with substantially more febrile neutropenia, mucositis and neuropathy. GOYA substituted obinutuzumab in 1,418 patients and got a hazard ratio of 0.92 that was not statistically significant, with more grade 3 to 5 and fatal adverse events, despite the same substitution working in follicular lymphoma and chronic lymphocytic leukaemia. REMARC added two years of lenalidomide maintenance and delayed progression without extending life. PHOENIX added ibrutinib and failed overall, helping patients under 60 and harming those over 60 by stopping them finishing the chemotherapy. What worked was subtraction and substitution rather than addition. FLYER showed that four cycles of R-CHOP with two extra rituximab doses was non-inferior to six in young patients with low-risk limited-stage disease, at three-year progression-free survival of 96 per cent and about a fifth fewer adverse events recorded (1,330 against 1,706). POLARIX replaced vincristine with polatuzumab vedotin and improved progression-free survival (hazard ratio 0.73) with no difference in overall survival at two years, the one positive result among these first-line trials.
Four large trials asked the same question from different directions: can a positron emission tomography scan after two cycles of chemotherapy decide what happens next. The answer turned out to be asymmetric. Intensifying on a positive scan worked at five years. EORTC H10 switched scan-positive early-stage patients from ABVD to escalated BEACOPP with involved-node radiotherapy and raised five-year progression-free survival from 77.4 to 90.6 per cent. At the preplanned ten-year analysis the difference was no longer statistically significant (hazard ratio 0.67, 95 per cent confidence interval 0.37 to 1.20). De-escalating on a negative scan works for chemotherapy. HD18 shortened escalated BEACOPP from six or eight cycles to four in scan-negative advanced disease with five-year progression-free survival of 92.2 against 90.8 per cent and half the severe infections; AHL2011 switched scan-negative patients to ABVD after two cycles of escalated BEACOPP with five-year progression-free survival of 85.7 against 86.2 per cent and grade 3 to 4 anaemia falling from 69 to 28 per cent. RATHL had already dropped bleomycin after a negative scan in advanced disease, with three-year progression-free survival of 84.4 against 85.7 per cent: just short of its non-inferiority margin, with less lung toxicity. De-escalating on a negative scan does not work for radiotherapy. HD16 omitted 20 Gy after a negative scan and lost 7.3 percentage points of five-year progression-free survival; H10 could not demonstrate non-inferiority in either risk group, and in the favourable group five-year progression-free survival was 99.0 per cent with radiotherapy against 87.1 per cent without.
Follicular lymphoma is treated in episodes across decades, so the questions are about duration and sequence rather than intensity. PRIMA randomised 1,018 responders to two years of rituximab maintenance or observation and reported median progression-free survival of 10.5 against 4.1 years at nine years, with ten-year overall survival of about 80 per cent in both arms: the cleanest demonstration in lymphoma that delaying progression and extending life are different things. Casulo gave the field the marker that matters. Of 588 patients given first-line R-CHOP, 19 per cent progressed within two years, and their five-year overall survival was 50 per cent against 90 per cent, with an index-adjusted hazard ratio of 6.44. Early progression now prompts a repeat biopsy, because transformation is often behind it (76 per cent of early progressions in one series of 296 patients given bendamustine and rituximab), and treatment that does not depend on chemotherapy sensitivity. For the rest of the disease the options multiplied. GALLIUM and RELEVANCE tested new first lines; ELARA and ZUMA-5 brought CAR-T, with complete responses in 69 and 74 per cent; ELM-2 and the other CD20 bispecific antibodies brought off-the-shelf alternatives, with a 73.4 per cent complete response rate for odronextamab; ROSEWOOD paired a Bruton tyrosine kinase inhibitor with a type II antibody; inMIND added a CD19 antibody to lenalidomide and rituximab for a progression-free survival hazard ratio of 0.43. In MALT lymphoma, one of the marginal zone lymphomas, IELSG-19 was, to its authors' knowledge, the first randomised trial of first-line systemic treatment.
ZUMA-1, JULIET and TRANSCEND NHL 001 established CD19 CAR-T in large B-cell lymphoma after two or more lines between 2017 and 2020, with objective responses in 73 per cent and complete responses in 53 per cent in the largest of them, and grade 3 or worse cytokine release syndrome in 2 per cent for lisocabtagene maraleucel against much higher rates for the other products. Then the three products split in the second line. ZUMA-7 and TRANSFORM both beat salvage chemotherapy with an autologous transplant. BELINDA, testing tisagenlecleucel in the same setting, did not: median event-free survival was 3.0 months in both arms. The explanation most often offered is the 52-day median interval from leukapheresis to infusion, during which 25.9 per cent of the CAR-T group progressed against 13.8 per cent of the standard-care group, compounded by a baseline imbalance that favoured the comparator. It is a cross-trial inference, and the fact that it is the best available explanation for a 322-patient randomised failure says something about how the field measures what it is doing. The CD20 bispecific antibodies arrived alongside and solved the logistics rather than the biology: no apheresis, no manufacturing wait, available the week the decision is made. STARGLO, EPCORE NHL-1, POLARGO and ECHELON-3 between them now give transplant-ineligible relapsed diffuse large B-cell lymphoma four options with randomised or pivotal evidence where a decade ago it had none.
LyMa established three years of rituximab maintenance after autologous transplantation in patients under 66, with four-year event-free survival of 79 against 61 per cent and an overall survival benefit at four years; at seven years the overall survival difference was no longer statistically significant (83.2 against 72.2 per cent, hazard ratio 0.63, 95 per cent confidence interval 0.37 to 1.08, p = 0.088), while seven-year progression-free survival remained 78.5 against 47.4 per cent. For older patients the question became where to put the Bruton tyrosine kinase inhibitor. SHINE added ibrutinib to bendamustine-rituximab and gained 28 months of progression-free survival (80.6 against 52.9 months, hazard ratio 0.75) with no survival difference. ECHO repeated the design with acalabrutinib and gained 17 months (66.4 against 49.6, hazard ratio 0.73), again with no survival difference and grade 3 or greater adverse events in roughly 89 per cent of both arms. ENRICH took the opposite route and removed the chemotherapy: ibrutinib with rituximab beat immunochemotherapy with an adjusted hazard ratio of 0.69, driven almost entirely by the comparison against R-CHOP (0.37) rather than against bendamustine-rituximab (0.91). TRIANGLE meanwhile asked whether the autologous transplant is still needed in patients aged 18 to 65 when ibrutinib is added to induction and maintenance. At a median follow-up of 54.9 months it was not: adding the transplant to ibrutinib did not improve failure-free survival (82 against 81 per cent at four years), and both ibrutinib groups had better four-year overall survival than transplant without ibrutinib (88 and 90 against 81 per cent). Taken together, a person over 60 with mantle cell lymphoma now has a chemotherapy-free first-line option, though SHINE and ECHO found no survival difference and the ENRICH abstract reports none, while a younger person has an ibrutinib-containing first line that has extended survival.
The T-cell lymphomas have far less randomised evidence than the B-cell lymphomas. JCOG9801 is one of very few controlled trials ever run exclusively in adult T-cell leukaemia/lymphoma: 118 patients, a complete response rate of 40 against 25 per cent for an intensive Japanese regimen over biweekly CHOP, three-year overall survival of 24 against 13 per cent that did not reach significance on two-sided testing, and grade 4 thrombocytopenia in 74 against 17 per cent. SMILE is a 38-patient single-arm phase 2 that made extranodal NK/T-cell lymphoma treatable, with an overall response rate of 79 per cent and one-year overall survival of 55 per cent, by building the regimen on asparaginase rather than on an anthracycline. Randomised comparisons of asparaginase regimens have since come from China: in 80 treated patients with advanced disease, pegaspargase-based DDGP gave a median progression-free survival that was not reached against 6.8 months with SMILE (hazard ratio 0.42), and in 248 patients with early-stage disease the oral-etoposide regimen ESA matched MESA on response rate with about half the severe adverse events. ECHELON-2 shows what is possible: brentuximab vedotin with CHP improved progression-free and overall survival in CD30-positive peripheral T-cell lymphoma in a global double-blind randomised trial. ALCANZA, an open-label randomised trial in CD30-positive cutaneous T-cell lymphoma, raised the rate of responses lasting at least four months from 12.5 to 56.3 per cent, which is a response endpoint rather than a survival one. Much else, including the choice of first-line regimen in peripheral T-cell lymphoma not otherwise specified, rests largely on single-arm studies and registry series. Several randomised trials are recruiting, in peripheral T-cell lymphoma with the T follicular helper phenotype and in NK/T-cell disease.
The Hodgkin de-escalation question gets its best-designed attempt yet. RADAR (NCT04685616, 1,042 estimated participants; recruiting) randomises ABVD against A2VD, which replaces the bleomycin with brentuximab vedotin, and omits radiotherapy entirely in anyone with a Deauville score of 1 to 3 after two cycles; primary completion is listed for September 2030. The oldest patients with diffuse large B-cell lymphoma finally get their own trials. POLAR BEAR (NCT04332822, 300 estimated participants; recruiting) tests polatuzumab vedotin in place of vincristine in R-miniCHOP in people aged 80 or over, or 75 or over and frail by a geriatric assessment, with a primary completion date of 28 December 2025 that has now passed; the registry record was last updated in September 2024, and no full report was indexed in PubMed on 17 November 2026. ARCHED (NCT05820841, 330 estimated participants; recruiting) adds acalabrutinib to R-miniCHOP, with primary completion listed for February 2029. The bispecific antibodies move to the front. A National Cancer Institute trial (NCT06337318, 600 estimated participants; recruiting) compares mosunetuzumab with rituximab as first treatment for low tumour burden follicular lymphoma, with primary completion listed for 31 March 2032, and a European trial (NCT06006117, 260 estimated participants; recruiting) runs mosunetuzumab with lenalidomide against the investigator's choice in relapsed marginal zone lymphoma, primary completion September 2027. In primary central nervous system lymphoma, PRIMA-CNS (NCT06830421, 340 estimated participants; recruiting) compares conventional immunochemotherapy with a short induction and an autologous transplant in elderly patients, primary completion 31 August 2029. FORTplus (NCT05045664, 100 estimated participants; recruiting) tests whether 4 Gy of radiotherapy with obinutuzumab is non-inferior to 24 Gy with rituximab in early follicular lymphoma, primary completion 30 September 2027.
First, the genetics have barely reached the clinic. Three classifications and a probabilistic tool exist, and standard first-line treatment is still not chosen by genetic subtype. One randomised phase 2, GUIDANCE-01, added targeted drugs to R-CHOP by a simplified genetic algorithm in 128 patients and raised the complete response rate from 66 to 88 per cent; a phase 3 trial of the same approach (NCT05351346, 1,100 planned participants) is registered, with a status the registry lists as unknown. Confirming that result at phase 3 is the clearest unfinished business in the disease. Second, nothing acts on a blood test. Circulating tumour DNA predicts outcome at diagnosis, detects residual disease better than imaging, reads cell of origin from plasma and shows patterns that may predict transformation, and no randomised trial has yet reported that changing treatment on the strength of it helps anyone. Third, the T-cell lymphomas have little randomised evidence. Adult T-cell leukaemia/lymphoma has had almost none: JCOG9801, reported in 2007, and a 53-patient randomised phase 2 reported in 2015. Fourth, access. Rituximab transformed B-cell lymphoma in 1997 and is still unavailable or unaffordable in much of the world; asparaginase, which makes NK/T-cell lymphoma treatable, is intermittently supplied; CAR-T requires an apheresis service, a cryopreservation chain and a centre able to manage cytokine release syndrome. The treatments on this page cure a high proportion of people with lymphoma, in the places that have them.
The piece that turns a research classification into something a trial can use on one person's biopsy, with a probability attached rather than a flat label. It is one of the tools that make genetics-directed lymphoma trials practical.
An early demonstration of how much circulating tumour DNA can show in lymphoma. It underpins the response-adapted trial designs now being built on molecular rather than radiographic response.
The Japanese standard regimen for aggressive adult T-cell leukaemia/lymphoma rests on this trial. Three-year overall survival of 24 per cent with the better arm is the plainest statement of how much room remains, and is why allogeneic transplantation, mogamulizumab and antiviral approaches have all been pursued since.
Every era's records, trial outcomes and papers, and every watch item, as JSON.
Readouts, decisions and registry completion dates ahead. Each date is quoted from its source, not inferred; a missing date means no source states one.
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
Loading this step…
The 48 most recent of 60 papers; see them all →
An option with a demonstrated survival benefit for transplant-ineligible relapsed diffuse large B-cell lymphoma, a group for whom very little has ever shown one. The fatal adverse event imbalance belongs in the conversation alongside the survival figure. The United States label for polatuzumab vedotin, read on 17 November 2026, lists it with bendamustine and a rituximab product for relapsed disease and does not list this combination.
A new combination for relapsed or refractory follicular lymphoma that adds a CD19-directed antibody to the established lenalidomide and rituximab pairing. The United States label added the combination for relapsed or refractory follicular lymphoma in June 2025, and says it is not indicated for marginal zone lymphoma outside controlled clinical trials.
A second randomised confirmation that adding a Bruton tyrosine kinase inhibitor to first-line bendamustine-rituximab delays progression in older patients with mantle cell lymphoma, with a toxicity profile that did not improve as much as the drug's selectivity promised. The United States label now includes acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma in adults ineligible for autologous stem-cell transplantation.
The evidence behind the United States approval of brentuximab vedotin with lenalidomide and a rituximab product for relapsed or refractory large B-cell lymphoma after two or more lines in patients not eligible for an autologous transplant or CAR-T. Almost 70 per cent of patients had CD30-negative tumours, and the authors report benefit regardless of CD30 expression.
The authors' conclusion is that ibrutinib-rituximab should be considered a new standard-of-care option for first-line treatment of older patients with mantle-cell lymphoma. The subgroup split means it is clearly better than R-CHOP and roughly equivalent to bendamustine-rituximab.
For fit younger patients treated in the intensive German tradition, BrECADD replaces escalated BEACOPP; how it compares with nivolumab-AVD from S1826 is the open question.
An off-the-shelf alternative to CAR-T for repeatedly relapsed follicular lymphoma: no apheresis, no manufacturing wait, and a complete response rate in the same range, at the cost of continued treatment rather than a single infusion.
Ibrutinib during induction and as maintenance should be part of first-line treatment for younger patients with mantle cell lymphoma; whether transplant adds anything to an ibrutinib-containing regimen is still being followed.
Shares Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER), Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03, FLYER, RELEVANCE.
Shares GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma, RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma, GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma, Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER).
Shares Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER), Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03, FLYER, RELEVANCE.
Shares Tafasitamab, Polatuzumab vedotin, Mosunetuzumab, Lisocabtagene maraleucel.
Shares GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma, ZUMA-1, Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER), Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03.
Shares Franck Morschhauser, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, REMARC, Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP.
Shares PRIMA-CNS, Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma, LyMa, POLARGO.
Shares Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, REMARC, Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP, Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/